Health Professional Radio - Podcast

STELARA® Phase 3 Extended UNIFI Study

Informações:

Sinopsis

Lead study investigator Dr. Bruce Sands, Icahn School of Medicine, Mt. Sinai, New York discusses Janssen's announcement of their new two-year data from the long-term extension of the Phase 3 UNIFI study of STELARA® (ustekinumab) that demonstrated long term efficacy and safety in adult patients with moderate to severe ulcerative colitis. This was presented as late-breaking data at the 27th United European Gastroenterology Week (UEGW) congress.